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A b s t r a c t
Background: An association between chronic heart failure (CHF) and pulmonary function abnormalities is clinicaly
important. Spirometry is frequently used to evaluate lung function.
Aim: To evaluate some spirometric parameters in the elderly with newly diagnosed or known systolic CHF.
Methods: The study group consisted of 110 patients (74 men – 67.3%) who underwent echocardiography as well as
spirometry with reversibility test. Heart failure was diagnosed using the guidelines of the European Society of Cardiology and
Framingham criteria. The average age of the patients was 68.5±8.9 years. Smokers constituted 54.5% of the group.
Concomittant deseaes included arterial hypertension (86.4%), diabetes type 2 (20.9%), and myocardial infarction (49.1%). At
the beginning of the study, 54.5% of the patients had already been taking beta-blockers, 84.5% angiotensin-converting enzyme
inhibitors, 83.6% diuretics, 30% calcium channel blockers, and 92.7% aspirin. Echocardiography revealed left ventricular ejection
fraction (LVEF) below 45% in 74 (67.3%) patients. 
Results: All analysed spirometric parameters were abnormal in CHF patients. A multivariable analysis revealed that age,
smoking and LVEF were the only independent parameters which significantly effected FEV1 – one of the most important
spirometric parameters. 
Conclusions: In patients with systolic CHF, independently of the treatment, mixed ventilation disorders were observed,
which had a positive reversibility test. Apart from impaired LVEF, older age as well as smoking significantly influenced the
deterioration of ventilatory parameters.
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Introduction
Chronic heart failure (CHF) affects 0.4-2.0% of the
European population and results from such common
diseases as hypertension, valve disorders and, most
often, ischaemic heart disease [1]. 
Heart failure is characterised by decreased blood
flow through the vital organs, including pulmonary
circulation. It is particulary associated with dysfunction
of the left ventricle (LV), biventricular failure and right
ventricular dysfunction coexisting with mitral stenosis
[2-6].
The relationship between CHF and respiratory
dysfunction was extensively studied, and the assessment
of respiratory function with spirometry, in addition to
the clinical, echocardiographic, radiological and
biochemical evaluation, gained a lot of  attention [1]. In
patients with pulmonary oedema, restrictive ventilatory
abnormalities were described, and they tended to be
present even before overt clinical manifestations or
radiological features of CHF. Mild or moderate
obstructive abnormalities most commonly coexist with
CHF, particularly when respiratory disorders are also
present [4].
Muscle weakness and peribronchial oedema are
considered to be responsible for the development and
exacerbation of respiratory tract disorders in patients
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with CHF [7, 8]. As a result, according to the few
published studies, patients with CHF, together with
higher respiratory flow resistance, measured by
oscilometric methods, as compared to healthy
individuals [9, 10]. 
The aim of the study was to evaluate selected
spirometric parameters of respiratory capacity in




The study included 110 patients with diagnosed
CHF based on the ESC 2001 criteria and treated in our
department between December 2003 and January
2005. The clinical criteria for inclusion in the study were
dyspnoea (exertional or nocturnal), peripheral oedema,
orthopnoea, signs of ischaemia in ECG, the presence of
rales over the lung fields, jugular filling, hepatomegaly
and positive hepatojugular reflux. Radiological criteria
included enlargement of the heart transverse
dimension as well as signs of congestion in the
pulmonary circulation.
The exclusion criteria were as follows: history of
bronchial asthma, chronic obstructive pulmonary
disease, tuberculosis or malignancy. 
The patients were treated with angiotensin-
-converting enzyme inhibitors (ACE-I), aspirin, diuretics,
calcium-channel blockers and beta-blockers. All
patients are given a questionnaire (including questions
about the clinical symptoms, the previous history of the
disease, current medications, addictions, risk factors,
and previous cardiovascular complications). Also
spirometry, both basic and post-dilatation (spirometric
assessment 20 minutes after inhalation of 200 ug of
salbutamol administered through the air chamber),
and echocardiography were performed. 
Spirometry
The spirometry test was performed using
a Lungtest 1000S device (MES, Cracow), according to
the recommendations of the European Respiratory
Society published in 1993 [11]. At least 3 repeatable
measurements of flow-volume curves were obtained
with particular attention to the measurement of the
following parameters: forced vital capacity (FVC),
forced expiratory volume during the first second of
expiration (FEV1), forced expiratory volume during the
first second of expiration after inhalation of
short-fast-acting beta-2-mimetic (FEV1R), peak
expiratory flow (PEF), and the maximum mean
expiratory flows between 75% and 25% of FVC (MEF75,
MEF50, MEF25).
Echocardiographic examination
Echocardiographic examination was performed with
a GE 3 Ultrasound device equipped with a 2.5-3.5 MHz
probe, in 2-D and M-mode, in parasternal and apical
views to assess systolic function of the LV. Left
ventricular ejection fraction (LVEF) was measured
planimetrically from a four-chamber apical view.
Statistical analysis 
The spirometric parameters were compared in
patients with LVEF <45% and ≥45%. The Statistica 6.0
software, normality tests, Student’s t-test, U Mann-
-Whitney test, χ2 test and Pearson correlation analysis
were utilised for initial statistical analysis. Multivariable
regression analysis was used to select factors
independently correlated with the analysed data. 
Results
A group of 110 patients – 36 (32.7%) women and 74
(67.3%) men was studied. The mean age of the
examined population was 68.5±8.9 years. Sixty (54.5%)
patients were current smokers. The comorbidities
included: hypertension (AH) in 86.4% of the patients,
type 2 diabetes mellitus (DM) in 20.9% of the patients
and history of myocardial infarction (MI) in 49.1% of the
patients. At baseline 54.5% of the individuals were
treated with beta-blockers, 84.5% received ACE-I, 83%
diuretics, 30% calcium channels blockers (CCB)
and 92.7% aspirin (ASA).
On echocardiography, LVEF <45% was found in 74
(67.3%) patients. 25.5% of the patients were in NYHA
class I, 17.3% in class II, 54.5% in class III and 2.7% in
class IV. The characteristics of the patients in relation to
the systolic function of the LV are presented in Table I. 
It was found that patients with decreased LVEF more
often had a history of MI and were treated with ACE-I,
diuretics, and calcium channels blockers; there were also
significantly more current smokers among them.
All the analysed spirometric parameters were
significantly reduced in the patients with LVEF <45%
(Table II). The patients with decreased contractility of
the LV were found to have mild to moderate mixed
ventilatory abnormalities, with mean reversibility of
obstruction amounting to 15.03%. In this group, the
volume criteria were also fulfilled, with a mean increase
of FEV1 in the dilatation test of 410 ml. In the patients
with normal contractility of the LV, the obstruction
reversibility test was negative, with a mean increase of
FEV1 of 5.71% (p=0.000017). 
To identify factors having a potential effect on the
ventilatory parameters in the examined group,
a multivariable statistical analysis was performed. The
following parameters having a potential impact on FEV1
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were included in the analysis: age, gender, LVEF, cigarette
smoking and used medications. 
A significant correlation between FEV1 and LVEF was
found (r=0.69, p <0.0001). When the variables showing
a significant correlation in the monofactorial analysis and
the patients’ gender were included in the multivariable
regression model, factors independently associated with
FEV1 values included age (beta=0.27±0.10; p=0.009),
cigarette smoking (beta=–0.28±0.09; p=0.002) and LVEF
(beta=0.78±0.10; p <0.001). The remaining correlations did
not reach statistical significance (Figure 1). 
Discussion
The ventilatory parameters assessed by spirometric
test in the patients with LV systolic dysfunction were
significantly lower compared with the patients with
normal systolic LV function. 
This suggests that the patients with CHF suffer for
mixed ventilatory abnormalities; however, it should be
remembered that in our study there were more
smokers among the patients with decreased LVEF,
Pulmonary function test abnormalities in the elderly with systolic heart failure 877
Parameter LVEF <45% LVEF ≥45% p
Number of patients 74 36
Males 48 (64.9%) 26 (72.1%) NS
Age [years] 69.2±9.09 68.3±10.27 NS
Smoking 45 (60.8%) 15 (41.7%) 0.05
Hypertension 70 (94.6%) 31 (86.1%) NS
Diabetes mellitus 39 (52.7%) 12 (33.3%) NS
Myocardial infarction 57 (77%) 9 (25%) 0.0001
Beta-blockers 44 (59.4%) 16 (44.4%) NS
Angiotensin-converting enzyme inhibitors 68 (91.9%) 25 (69.4%) 0.001
Diuretics 73 (98.6%) 19 (52.8%) 0.0001
Calcium channel blockers 27 (36.5%) 6 (16.7%) 0.01
Aspirin 71 (95.9%) 31 (86.1%) NS
LVEF 35.2±5.09 54.2±6.93 0.0001
Table I. Comparison of patients with normal (LVEF ≥45%) or impaired (LVEF <45%) LV systolic function 
Parameter LVEF <45% LVEF ≥45
Number of patients 74 36
FEV1 [l] 1.41±0.6 2.58±0.87*
FEV1 [%N] 51.31±19.83 91.00±20.82*
FEV1R [%N] 66.34±23.47 96.71±20.12*
FEV1R – FEV1 [l] 0.41±0.17 0.16±0.05*
FVC [l] 2.55±0.69 3.53±0.94*
FVC [%N] 71.55±0.55 97.10±0.94*
FEV1%FVC 73.31±19.51 97.23±11.58*
PEF [%N] 37.05±23.16 71.8±29.13*
Table II. Spirometric parameters in relation to
the presence of systolic CHF
* p <0.0001
Abbreviations: FVC – forced vital capacity, FEV1 – forced expiratory
volume during the first second of expiration, FEV1R – forced
expiratory volume during the first second of expiration after
inhalation of 200 μg of salbutamol, FEV1R – FEV1 – difference in
the rise of forced expiratory volume during the first second of
expiration after the inhalation test, VC – vital capacity, FEV1%FVC
– FEV1/FVC rate × 100%, PEF – peak expiratory flow
%N – the percentage of a due value; due values were assessed on
the basis of guidelines provided by: Standardization of lung
function tests, 1993 update. Official statement European
Respiratory Society. Eur Respir J 1993; 6 (Suppl. 16): 41–53









Figure 1. The relationship between LVEF, FEV1
and FEV1R in examined population (p <0.0001)
Abbreviations: LVEF – left ventricular ejecion fraction, FEV1
– forced expiratory volume during the first second of expiration,
FEV1R – forced expiratory volume during the first second of
expiration after inhalation of 200 μg of salbutamol
% of patients
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which could have affected the final result. Nevertheless,
a possible coexistence of CHF and chronic obstructive
pulmonary disease in the study group should be
considered. The published data suggest that mild to
moderate obstruction usually accompanies CHF,
particularly if respiratory disorders are also present
[4, 12-14].
In the patients with pulmonary oedema, restrictive
ventilatory abnormalities were reported, which might
be present even before the clinical or radiological
symptoms occur. Even though the respiratory system
changes were more significant in the patients with the
right ventricular failure, a relationship between the
degree of these changes and the severity of CHF was
noted, which might be explained by muscle weakness
and peribronchial oedema observed in this group of
patients [4, 7, 8]. Moreover, in comparison to healthy
individuals, the patients with CHF have higher airflow
resistance, measured with oscilometric method [9]. In
the examined group of patients, more abnormal results
obtained in the spirometric test were due to not only
impaired systolic function of the LV, but also to
cigarette smoking and the older age of the examined
population. In the smoking patients, the annual
decrease of FEV1 assessed with the use of serial
spirometric tests is known to become more intense
with age. It is particularly evident in white males [15]. 
In our study, the patients with impaired systolic
function of the LV showed mild to moderate mixed
ventilatory abnormalities, with obstruction reversibility
of 15.03% (compared with the initial value); the volume
criteria were also fulfilled, with a mean increase of FEV1
in dilatation test of 410 ml. Such a good response to
inhaled bronchodilatory agents might suggest that
there are many individuals with undiagnosed bronchial
asthma in the group of patients with decreased LVEF. It
should be considered that, also in healthy subjects,
ventilatory parameters possibly improve after
inhalation of beta-mimetic agents, but never to such an
extent. Furthermore, together with the decrease of VC
observed in this group of patients, the presence of
restrictive ventilatory disorders might also be
suggested. In order to unequivocally assess the type of
pathology, total lung capacity (TLC) should be assessed,
using, for example, plethysmographic examination. 
The effect of beta-blockers used in the treatment of
CHF on the spirometric parameters did not reach
statistical significance in multivariable analysis. The lack
of such a correlation could be explained by a much
stronger influence of the impaired LV systolic function on
ventilatory parameters, as well as by a more
cardioselective action of currently used medications.
Such a correlation was previously demonstrated by many
investigators, and confirmed by Grosgurin et al. and
Salpeter et al. [16, 17]. Even though the use of beta
blockers did not significantly influence the ventilatory
parameters, it might be assumed that the analysis of the
effects of individual agents on spirometric parameters
could reveal significant impact of some of them. 
Even though the spirometric test is relatively easy
to perform and its results are reproducible [18-20],
some difficulties might occur in the group of older
patients, limiting good cooperation between patients
and medical staff. Such difficulties very often prevent
proper conduction of the spirometric examination. In
elderly patients, it might be very difficult or even
impossible to obtain an adequate and repeatable result
due to deafness, vision disorders, motor function
impairment and frequent neurological complications of
chronic disorders. A slight weakness of respiratory
muscles, particularly of the diaphragm, was also
observed in the patients with CHF, which was
associated mostly with the predominance of free fibres
in the diaphragm’s structure [11], as well as with
profound metabolic abnormalities in the skeletal
muscles, leading to their dysfunction. Along with the
difficulties resulting from the possible imperfect
cooperation with the examined patients, another
limiting factor is the lack of residual volume
measurement that can be performed only by cabinet
plethysmography, which enables precise identification
of mixed (obstructive-restrictive) respiratory
abnormalities. 
Conclusion
In patients with systolic CHF, irrespectively of the
administered treatment, mixed ventilatory abnormalities
were observed and showed a good response to inhaled
bronchodilatory agents (mean increase of 15.03%
compared to baseline values). Besides, the impaired
systolic function of the LV, cigarette smoking and older age
of the subjects significantly worsened the ventilatory
parameters in the studied group of patients.
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S t r e s z c z e n i e
Wstęp: Związek między niewydolnością serca i dysfunkcją układu oddechowego jest przedmiotem intensywnych badań. Coraz
ważniejsze miejsce zajmuje – obok oceny klinicznej, echokardiograficznej, radiologicznej czy wreszcie biochemicznej – ocena
wydolności układu oddechowego metodą spirometryczną. U chorych z obrzękiem płuc opisywano upośledzenie wentylacji
o cechach restrykcji, które może się pojawić nawet przed wystąpieniem objawów klinicznych czy cech radiologicznych.
Niewydolności serca najczęściej towarzyszą łagodne lub umiarkowane cechy obturacji, zwłaszcza jeśli u chorych współistnieją
przewlekłe schorzenia układu oddechowego. 
Cel: Ocena wybranych spirometrycznych parametrów wydolności układu oddechowego u chorych ze świeżo rozpoznaną lub
leczoną niewydolnością serca. 
Metodyka: Do badania zakwalifikowano grupę 110 chorych z niewydolnością serca – w tym 74 (67,3%) mężczyzn. U wszystkich
wykonano badanie echokardiograficzne oraz badanie spirometryczne z próbą rozkurczową. Niewydolność serca stwierdzono, opierając
się na wytycznych European Society of Cardiology oraz kryteriach Framingham. Badanie spirometryczne i próbę rozkurczową, czyli
ponowne badanie spirometryczne po 20 min od podania 200 μg wziewnego salbutamolu, wykonano zgodnie z zaleceniami European
Respiratory Society z 1993 r. Kryteria wyłączające stanowiły: astma oskrzelowa, przewlekła obturacyjna choroba płuc, gruźlica i choroba
nowotworowa w wywiadzie. Średni wiek badanej populacji wyniósł 68,5±8,9 roku. Aktywne palenie tytoniu w wywiadzie podawało 60
(54,5%) osób. Wśród chorób towarzyszących nadciśnienie tętnicze występowało u 86,4%, cukrzyca typu 2 u 20,9%, zawał mięśnia
sercowego (MI) w wywiadzie u 49,1% badanych. W leczeniu, w chwili włączenia do badania, beta-blokery stosowało 54,5%, inhibitory
enzymu konwertującego angiotensynę (ACE-I) 84,5%, diuretyki 83,6%, blokery kanału wapniowego 30%, kwas acetylosalicylowy 92,7%
osób. W badaniu echokardiograficznym frakcję wyrzutową lewej komory (LVEF) <45% wykazano u 74 (67,3%) osób. Stwierdzono, że
chorzy z obniżoną LVEF charakteryzowali się częstszym występowaniem MI w wywiadzie oraz częstszym przyjmowaniem ACE-I,
diuretyków i blokerów kanału wapniowego, w grupie tej było także istotnie więcej osób ciągle palących papierosy. Porównania
parametrów spirometrycznych dokonano w grupach chorych z LVEF >45% i LVEF ≤45%. Przy użyciu pakietu Statistica 6.0, we wstępnej
analizie statystycznej wykorzystano testy normalności, test t-Studenta, test U Manna-Whitneya, test χ2 oraz analizę korelacji Pearsona.
W celu wyodrębnienia czynników niezależnie powiązanych z analizowanymi zmiennymi wykorzystano wieloczynnikową analizę regresji. 
Wyniki: Wszystkie analizowane parametry spirometryczne były wyraźnie niższe u chorych z niewydolnością serca. U chorych
z upośledzoną kurczliwością lewej komory stwierdzono umiarkowane i średnie zaburzenia wentylacji o typie mieszanym (ze średnią
odwracalnością obturacji wynoszącą 15,03% badanej w stosunku do wartości początkowej), w tej grupie spełnione było także kryterium
objętościowe, tj. średni przyrost natężonej objętości wydechowej pierwszosekundowej w próbie rozkurczowej wynosił 410 ml. W grupie
chorych z zachowaną czynnością skurczową komory test odwracalności obturacji był ujemny, tzn. średni przyrost natężonej objętości
wydechowej pierwszosekundowej wyniósł 5,71% (160 ml). Po przeprowadzeniu analizy statystycznej wykazano, iż parametrami
wpływającymi na natężoną objętość wydechową pierwszosekundową były wiek, palenie tytoniu oraz LVEF. Pozostałe zależności nie
osiągnęły znamienności statystycznej. 
Wnioski: U chorych ze skurczową niewydolnością serca, niezależnie od stosowanego leczenia, obserwowano mieszane
zaburzenia oddechowe z komponentą obturacyjną i dodatnią próbę rozkurczową. Obok upośledzonej czynności skurczowej
lewej komory, na pogorszenie parametrów oddechowych w badanej grupie chorych wpływ miały także starszy wiek i palenie
tytoniu. 
Słowa kluczowe: spirometria, niewydolność serca 
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